| P/E (FY) | — | Sales (TTM) | JPY 4.58T |
| Earnings (TTM) | JPY 107.93B | ROE | 1.52% |
| Net Margin | 2.36% | ROIC | 1.86% |
| Debt / Equity | 0.65 | TD / EBITDA | 4.09 |
| EPS Growth 3Y | −22.76% | Sales Growth 3Y | 8.68% |
Takeda Pharmaceutical Company researches, develops, manufactures, markets, and out-licenses pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Its products are sold under brands including Entyvio, Takhzyro, Advate, Vpriv, Adcetris, Ninlaro, Iclusig, Vyvanse, Trintellix, and QDENGA. The company maintains licensing and collaboration agreements with partners such as Arrowhead Pharmaceuticals, Halozyme, and Mirum Pharmaceuticals.
| Market Cap | — | Trading Days | 4164 |
| 52W High | 18.89 |
| 52W Low | 12.99 |
| % Off High | −8.71% |
| YTD | 10.65% | 1Y | 26.84% |
| 3Y | 20.75% | 5Y | 11.67% |
| 10Y | −20.92% | Since incept. (ann.) | −0.89% |
| Ann. Volatility (1Y) | 21.48% | Ann. Volatility (3Y) | 19.74% |
| Sharpe (1Y) | 0.99 | Sharpe (3Y) | 0.42 |
| Max Drawdown (1Y) | −20.05% | Max Drawdown (3Y) | −21.20% |
| Beta (3Y, vs SPY) | −0.26 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.90B | 18.2 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $122.67B | 31.5 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.34B | 16.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.35B | 123.0 |